IMPORTANCE
Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma
II
interventionell
National
Pembrolizumab
Status: In Rekrutierung
Zeitraum
2018
2024
Zentren
8
8
Keine Zentren gesucht
Patienten
130
114
20.03.2024
Klinische Settings
2nd line
kurativ
Identifier
AIO-KHT-0222/ass
AIO-KHT-0222/ass
2017-002122-20
Kontakt
Leitung
Prof. Dr. med. Rainer Fietkau
Ansprechpartner*in
Dr. rer. nat. Annett Kallies
Telefon +49 9131 8533968
E-Mail annett.kallies@uk-erlangen.de